他克莫司與環孢素A比較治療胰腎聯合移植術后排斥反應的Meta分析_《中國循證醫學雜志》

作者：

吳斌 , 盧靜 , 李健 , 柳汝明 ,  唐堯

四川大學華西醫院藥劑科（成都 610041）;

關鍵詞：

胰腎聯合移植免疫抑制他克莫司環孢素 Meta 分析

DOI：

10.7507/1672-2531.20090218

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

目的　評價他克莫司（TAC）與環孢素A（CSA）治療胰腎聯合移植（SPKT）術后排斥反應的療效和安全性。
方法　檢索Cochrane 圖書館、MEDLINE、EMbase、SCI、CBM 數據庫（檢索時間從建庫至2009 年3 月），納入比較TAC 與CSA 治療SPKT 術后排斥反應的隨機對照試驗（RCT），采用Cochrane 協作網推薦的方法進行質量評價和Meta 分析。
結果　共納入5 個RCT，合計342 例患者。Meta 分析結果顯示：TAC 組胰腺存活率高于CSA組［RR=1.15，95%CI（1.04，1.27）］；［RD=0.11，95%CI（0.03，0.19）］，但兩組急性排斥反應、病人存活率、腎臟存活率及感染情況差異無統計學意義，其RR（95%CI）分別為0.81（0.58，1.12）、1.00（0.94，1.05）、1.02（0.95，1.09）和1.00（0.83，1.20）。
結論　基于當前證據，TAC 與CSA 比較治療SPKT 術后排斥反應能提高胰腺存活率。治療100例SPKT 患者，TAC 比CSA 多讓11 例患者的胰腺存活。

引用本文： 吳斌,盧靜,李健,柳汝明,唐堯. 他克莫司與環孢素A比較治療胰腎聯合移植術后排斥反應的Meta分析. 中國循證醫學雜志, 2009, 09(11): 1214-1219. doi: 10.7507/1672-2531.20090218 復制

1.	Kelly WD, Lillehei RC, Merkel FK, et al. Allotransplantation of the pancreas and duodenum along with the kidney in diabetic nephropathy. Surgery, 1967, 61(6): 827-837.
2.	Knoll GA, Nichol G. Dialysis, kidney transplantation, or pancreas transplantation for patients with diabetes mellitus and renal failure: a decision analysis of treatment options. J Am Soc Nephrol, 2003, 14(2): 500-515.
3.	Arbogast H, Malaise J, Illner WD, et al. Rejection after simultaneous pancreas-kidney transplantation. Nephrol Dial Transplant, 2005, 20(Suppl 2): ii11-17.
4.	Singh RP, Stratta RJ. Advances in immunosuppression for pancreas transplantation. Curr Opin Organ Transplant, 2008, 13(1): 79-84.
5.	Sutherland DE, Gores PF, Farney AC, et al. Evolution of kidney, pancreas, and islet transplantation for patients with diabetes at the University of Minnesota. Am J Surg, 1993, 166(5): 456-491.
6.	Richter A, Davies DE, Alexander P. Growth inhibitory effects of FK506 and cyclosporin A independent of inhibition of calcineurin. Biochem Pharmacol, 1995, 49(3): 367-373.
7.	Boggi U, Vistoli F, Del Chiaro M, et al. Single-center, open, prospective, randomized pilot study comparing cyclosporine versus tacrolimus in simultaneous pancreas-kidney transplantation. Transplant Proc, 2004, 36(4): 1064-1066.
8.	Boggi U, Vistoli F, Del Chiaro M, et al. Neoral versus Prograf in simultaneous pancreas-kidney transplantation with portal venous drainage: Three-year results of a single-center, open-label, prospective, randomized pilot study. Transplant Proc, 2005, 37(6): 2641-2643.
9.	Bechstein WO, Malaise J, Saudek F, et al. Efficacy and safety of tacrolimus compared with cyclosporine microemulsion in primary simultaneous pancreas-kidney transplantation: 1-year results of a large multicenter trial. Transplantation, 2004, 77(8): 1221-1228.
10.	Saudek F, Malaise J, Boucek P, et al. Efficacy and safety of tacrolimus compared with cyclosporin microemulsion in primary SPK transplantation: 3-year results of the Euro-SPK 001 trial. Nephrol Dial Transplant, 2005, 20(Suppl 2): ii3-10.
11.	Woeste G, Wullstein C, Dette K, et al. Tacrolimus/mycophenolate mofetil vs cyclosporine A/Azathioprine after simultaneous pancreas and kidney transplantation: Five-year results of a randomized study. Transplant Proc, 2002, 34(5): 1920-1921.
12.	Schulz T, Konzack J , Büsing M. Mycophenolate mofet i l / prednisolone/single-shot ATG with tacrolimus or cyclosporine in pancreas/kidney transplantation: first results of an ongoing prospective randomized trial. Transplant Proc, 1999, 31(1-2): 591-592.
13.	Stegall MD, Simon M, Wachs ME, et al. Mycophenolate mofetil decreases rejection in simultaneous pancreas-kidney transplantation when combined with tacrolimus or cyclosporine. Transplantation, 1997, 64(12): 1695-1700.
14.	Schmied BM, Müller SA, Mehrabi A, et al. Immunosuppressive standards in simultaneous kidney-pancreas transplantation. Clin Transplant, 2006, 20(Suppl 17): 44-50.
15.	Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008. Available at: www.cochranehandbook. org.
16.	Cochrane W. The combination of estimates from different experiments. Biometrics, 1954, 10(1): 101-129.
17.	Ye F, Ying-Bin X, Yu-Guo W, et al. Tacrolimus versus cyclosporine microemulsion for heart transplant recipients: a meta-analysis. J Heart Lung Transplant, 2009, 28(1): 58-66.
18.	McAl i s ter VC, Haddad E, Renouf E, e t al . Cyclospor i n versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis. Am J Transplant, 2006, 6(7): 1578-1585.
19.	Webster AC, Woodroffe RC, Taylor RS, et al. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ, 2005, 331(7520): 810.
20.	Drachenberg CB, Klassen DK, Weir MR, et al. Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation. Transplantation, 1999, 68(3): 396-402.
21.	Delis S, Dervenis C, Bramis J, et al. Vascular complications of pancreas transplantation. Pancreas, 2004, 28(24): 413-420.
22.	Steurer W, Malaise J, Mark W, et al. Spectrum of surgical complications after simultaneous pancreas-kidney transplantation in a prospectively randomized study of two immunosuppressive protocols. Nephrol Dial Transplant, 2005, 20(Suppl 2): ii54-62.

1. Kelly WD, Lillehei RC, Merkel FK, et al. Allotransplantation of the pancreas and duodenum along with the kidney in diabetic nephropathy. Surgery, 1967, 61(6): 827-837.
2. Knoll GA, Nichol G. Dialysis, kidney transplantation, or pancreas transplantation for patients with diabetes mellitus and renal failure: a decision analysis of treatment options. J Am Soc Nephrol, 2003, 14(2): 500-515.
3. Arbogast H, Malaise J, Illner WD, et al. Rejection after simultaneous pancreas-kidney transplantation. Nephrol Dial Transplant, 2005, 20(Suppl 2): ii11-17.
4. Singh RP, Stratta RJ. Advances in immunosuppression for pancreas transplantation. Curr Opin Organ Transplant, 2008, 13(1): 79-84.
5. Sutherland DE, Gores PF, Farney AC, et al. Evolution of kidney, pancreas, and islet transplantation for patients with diabetes at the University of Minnesota. Am J Surg, 1993, 166(5): 456-491.
6. Richter A, Davies DE, Alexander P. Growth inhibitory effects of FK506 and cyclosporin A independent of inhibition of calcineurin. Biochem Pharmacol, 1995, 49(3): 367-373.
7. Boggi U, Vistoli F, Del Chiaro M, et al. Single-center, open, prospective, randomized pilot study comparing cyclosporine versus tacrolimus in simultaneous pancreas-kidney transplantation. Transplant Proc, 2004, 36(4): 1064-1066.
8. Boggi U, Vistoli F, Del Chiaro M, et al. Neoral versus Prograf in simultaneous pancreas-kidney transplantation with portal venous drainage: Three-year results of a single-center, open-label, prospective, randomized pilot study. Transplant Proc, 2005, 37(6): 2641-2643.
9. Bechstein WO, Malaise J, Saudek F, et al. Efficacy and safety of tacrolimus compared with cyclosporine microemulsion in primary simultaneous pancreas-kidney transplantation: 1-year results of a large multicenter trial. Transplantation, 2004, 77(8): 1221-1228.
10. Saudek F, Malaise J, Boucek P, et al. Efficacy and safety of tacrolimus compared with cyclosporin microemulsion in primary SPK transplantation: 3-year results of the Euro-SPK 001 trial. Nephrol Dial Transplant, 2005, 20(Suppl 2): ii3-10.
11. Woeste G, Wullstein C, Dette K, et al. Tacrolimus/mycophenolate mofetil vs cyclosporine A/Azathioprine after simultaneous pancreas and kidney transplantation: Five-year results of a randomized study. Transplant Proc, 2002, 34(5): 1920-1921.
12. Schulz T, Konzack J , Büsing M. Mycophenolate mofet i l / prednisolone/single-shot ATG with tacrolimus or cyclosporine in pancreas/kidney transplantation: first results of an ongoing prospective randomized trial. Transplant Proc, 1999, 31(1-2): 591-592.
13. Stegall MD, Simon M, Wachs ME, et al. Mycophenolate mofetil decreases rejection in simultaneous pancreas-kidney transplantation when combined with tacrolimus or cyclosporine. Transplantation, 1997, 64(12): 1695-1700.
14. Schmied BM, Müller SA, Mehrabi A, et al. Immunosuppressive standards in simultaneous kidney-pancreas transplantation. Clin Transplant, 2006, 20(Suppl 17): 44-50.
15. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008. Available at: www.cochranehandbook. org.
16. Cochrane W. The combination of estimates from different experiments. Biometrics, 1954, 10(1): 101-129.
17. Ye F, Ying-Bin X, Yu-Guo W, et al. Tacrolimus versus cyclosporine microemulsion for heart transplant recipients: a meta-analysis. J Heart Lung Transplant, 2009, 28(1): 58-66.
18. McAl i s ter VC, Haddad E, Renouf E, e t al . Cyclospor i n versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis. Am J Transplant, 2006, 6(7): 1578-1585.
19. Webster AC, Woodroffe RC, Taylor RS, et al. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ, 2005, 331(7520): 810.
20. Drachenberg CB, Klassen DK, Weir MR, et al. Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation. Transplantation, 1999, 68(3): 396-402.
21. Delis S, Dervenis C, Bramis J, et al. Vascular complications of pancreas transplantation. Pancreas, 2004, 28(24): 413-420.
22. Steurer W, Malaise J, Mark W, et al. Spectrum of surgical complications after simultaneous pancreas-kidney transplantation in a prospectively randomized study of two immunosuppressive protocols. Nephrol Dial Transplant, 2005, 20(Suppl 2): ii54-62.

上一篇
醋柳黃酮治療原發性高血壓的系統評價
下一篇
依西美坦治療絕經后婦女乳腺癌療效的系統評價

《中國循證醫學雜志》

他克莫司與環孢素A比較治療胰腎聯合移植術后排斥反應的Meta分析

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

上一篇

下一篇

Format

Content

《中國循證醫學雜志》

他克莫司與環孢素A比較治療胰腎聯合移植術后排斥反應的Meta分析

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

上一篇

下一篇

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料